Aller au contenu principal

HIPRA will have a COVID-19 vaccine adapted to the JN.1 variant

Entreprise

The biotechnological pharmaceutical company HIPRA will have a vaccine against COVID-19 adapted to the JN.1 variant, thus complying with the new recommendations of the EMA and the WHO which propose to update the composition of the vaccines for the next autumn vaccination campaign.

HIPRA, thanks to the continuous epidemiological monitoring, anticipated the recommendations and started the development of the new adapted vaccine and the manufacture of the first batches, being able to guarantee the supply of doses for the population.

The adapted recombinant protein adjuvanted vaccine will be available in single-dose format. The results of the in vivo studies available to date demonstrate that the HIPRA vaccine generates good levels of neutralizing antibodies against this new family of variants in both primary vaccination and booster studies.

HIPRA will have a COVID-19 vaccine adapted to the JN.1 variant